bjh research paper

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

Michael Grövdal,[1] Mohsen Karimi,[1] Rasheed Khan,[1] Anni Aggerholm,[2] Petar Antunovic,[3] Jan Astermark,[4] Per Bernell,[5] Lena-Maria Engström,[6] Lars Kjeldsen,[7] Olle Linder,[8] Lars Nilsson,[9] Anna Olsson,[10] Mette S. Holm,[2] Jon M. Tangen,[11] Jonas Wallvik,[12] Gunnar Öberg,[13] Peter Hokland,[2] Sten E. Jacobsen,[9] Anna Porwit[14] and Eva Hellström-Lindberg[1]

[1]*Division of Haematology, Department of Medicine, Centre for Experimental Haematology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden,* [2]*Department of Haematology, Aarhus University Hospital, Aarhus, Denmark,* [3]*Department of Haematology, Linköping University Hospital, Linköping,* [4]*Department for Haematology and Coagulation Disorders, Malmö University Hospital, Malmö,* [5]*Karolinska University Hospital Solna, Stockholm,* [6]*Department of Haematology, University of Norrland, Umeå, Sweden,* [7]*Department of Haematology, Rigshospitalet, København, Denmark,* [8]*Department of Medicine, Örebro University Hospital, Örebro,* [9]*Haematopoietic Stem Cell Laboratory and Department of Haematology, Lund University Hospital, Lund,* [10]*Department of Haematology, Sahlgrenska University Hospital, Göteborg, Sweden,* [11]*Department of Haematology, Ullevål University Hospital, Oslo, Norway,* [12]*Department of Medicine, Sundsvall Hospital, Sundsvall,* [13]*Department of Haematology, Academic Hospital, Uppsala, and* [14]*Department of Pathology, Karolinska University Hospital Solna, Stockholm, Sweden*

Received 3 February 2010; accepted for publication 13 April 2010

Correspondence: Michael Grövdal, Division of Haematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.
E-mail: michael.grovdal@ki.se

Summary

This prospective Phase II study is the first to assess the feasibility and efficacy of maintenance 5-azacytidine for older patients with high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia and MDS-acute myeloid leukaemia syndromes in complete remission (CR) after induction chemotherapy. Sixty patients were enrolled and treated by standard induction chemotherapy. Patients that reached CR started maintenance therapy with subcutaneous azacytidine, 5/28 d until relapse. Promoter-methylation status of *CDKN2B* (*P15 ink4b*), *CDH1* and *HIC1* was examined pre-induction, in CR and 6, 12 and 24 months post CR. Twenty-four (40%) patients achieved CR after induction chemotherapy and 23 started maintenance treatment with azacytidine. Median CR duration was 13·5 months, >24 months in 17% of the patients, and 18–30·5 months in the four patients with trisomy 8. CR duration was not associated with *CDKN2B* methylation status or karyotype. Median overall survival was 20 months. Hypermethylation of *CDH1* was significantly associated with low CR rate, early relapse, and short overall survival ($P = 0{\cdot}003$). 5-azacytidine treatment, at a dose of 60 mg/m^2 was well tolerated. Grade III-IV thrombocytopenia and neutropenia occurred after 9·5 and 30% of the cycles, respectively, while haemoglobin levels increased during treatment. 5-azacytidine treatment is safe, feasible and may be of benefit in a subset of patients.

Keywords: myelodysplastic syndrome, azacytidine, clinical studies, maintenance therapy, DNA-methylation.

First published online 20 May 2010
doi:10.1111/j.1365-2141.2010.08235.x

Until recently, standard treatment in the Nordic countries for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) following MDS (MDS-AML) not eligible for stem cell transplantation has been standard induction chemotherapy or only supportive care including palliative chemotherapy. Several studies showed that around 50% (41–56%) of such patients reach a complete remission (CR). However, CR durations are short with almost no long-term survivors (Wattel *et al*, 1997; Ganser *et al*, 2000; Hast *et al*, 2003; Kantarjian *et al*, 2006a; Hofmann *et al*, 2007) and standard consolidation chemotherapy is not associated with prolonged CR (Wattel *et al*, 1997; Ganser *et al*, 2000; Hast *et al*, 2003; Kantarjian *et al*, 2006b; Hofmann *et al*, 2007). The dismal prognosis for these patients lead to the search for other treatment regimens, of which demethylating therapy is the most promising. In 2002, a randomized study comparing 5-azacytidine (azacytidine) to best supportive care only, reported prolonged time to the composite endpoint leukaemic transformation or death in the azacytidine-treated group (Silverman *et al*, 2002). Also decitabine, another hypomethylating agent, was shown to be effective in MDS (Lübbert *et al*, 2001). This led us to hypothesize that maintenance treatment with azacytidine for patients in CR after induction chemotherapy might prolong time to relapse and survival. Azacytidine was initially used in high-doses for the treatment of patients with AML but was abandoned in favour of other agents due to severe gastrointestinal side effects and prolonged myelotoxicity (O'Dwyer & Maslak, 2008). In lower doses, however, azacytidine was later shown to cause DNA demethylation by irreversible inhibition of DNA methyl transferases (Singal & Ginder, 1999; Esteller, 2008; Grønbaek *et al*, 2008). The exact mechanisms of action *in vivo* are not known but it is clear that it can cause hypomethylation and re-expression of previously silenced genes as well as induction of apoptosis and immunomodulation (Daskalakis *et al*, 2002; Schmeltz *et al*, 2005; Guo *et al*, 2006; Berg *et al*, 2007; Khan *et al*, 2008; Sánchez-Abarca *et al*, 2010). Genes previously known to be frequently methylated in MDS include *CDKN2B* (*P15ink4b*), *E-cadherin* (*CDH1*) and *Hypermethylated in Cancer 1* (*HIC1*). Promoter-methylation of these genes has also been reported to be associated with poor prognosis and leukaemic transformation of MDS (Tien *et al*, 2001; Christiansen *et al*, 2003; Aggerholm *et al*, 2006). We recently reported a strong association between promoter-methylation of *CDH1* or of more than one of these three genes and failure to induction chemotherapy (Grövdal *et al*, 2007). The present study was designed to assess the feasibility and efficacy of long-term maintenance treatment with azacytidine in a cohort of elderly patients with high-risk MDS and AML following MDS in CR after conventional induction chemotherapy.

Materials and methods

Patients

Patients with intermediate-2 or high-risk MDS, chronic myelomonocytic leukaemia (CMML) with >10% blasts or with AML following a documented MDS phase, according to the World Health Organization (WHO) 2001 classification (Jaffe *et al*, 2001) and the International Prognostic Scoring System (IPSS) (Greenberg *et al*, 1997), were eligible for the protocol. Patients should not be eligible for AML-like induction chemotherapy followed by intensive consolidation courses and allogeneic stem cell transplantation, but should be considered to tolerate at least one cycle of standard induction chemotherapy. The study was approved by ethical committees and medical product agencies of the participating Nordic countries. All patients gave their written informed consent. Diagnosis as well as CR was verified at a central haematopathology unit according to established Nordic MDS Group routines (Jädersten *et al*, 2005; Grövdal *et al*, 2007). Bone marrow cellularity was assessed on bone marrow biopsies and the percentage of blasts in bone marrow smears was determined by counting 500 cells in representative areas. Cytogenetic analyses were performed locally only at enrolment, using standard techniques, and patients were classified according to the IPSS into good, intermediate, or poor prognostic subgroups (Greenberg *et al*, 1997). The criteria for CR were <5% bone marrow blasts, stable haemoglobin >100 g/l, white blood cell count $>1{\cdot}5 \times 10^9$/l with normal differential count and platelets $>100 \times 10^9$/l. Persistent dysplastic features were allowed.

Study design

Induction chemotherapy consisted of a DA regimen: daunorubicin 60 mg/m^2 i.v. day 1 and 2 and cytarabine 150 mg/m^2 s.c. or i.v. days 1–7. Patients could receive a second induction if they did not reach CR on the first one and were judged fit enough by their treating physician. No standard consolidation courses were given. Patients that did not reach CR were given best supportive care with or without low-dose palliative chemotherapy, such as hydroxycarbamide, according to the choice of the treating physician and were followed only for survival. Patients achieving CR started maintenance therapy with azacytidine given subcutaneously 5/28 d starting within 28 d from CR. The protocol was specifically aimed at administering this treatment on an outpatient basis, and prolonged grade 4 haematological adverse events therefore constituted a basis for dose reduction. Initial azacytidine dose was 75 mg/m^2 but, due to high incidence of grade 4 neutropenia in the first five enrolled patients, the protocol was amended and the starting dose was reduced to 60 mg/m^2.

 © 2010 Blackwell Publishing Ltd,

Further reduction of the azacytidine dose was also allowed to avoid severe cytopenias and hospitalization. Patients continued on azacytidine until relapse or intolerable toxicity. Anti-emetic treatment was given prior to azacytidine. The primary endpoint was duration of CR and secondary endpoints were overall survival (OS) and the impact of pre-treatment parameters on prognosis.

Bone marrow sampling, DNA isolation and bisulfite modification

Bone marrow for methylation analyses was sampled in standardized flasks and medium at enrolment, at CR and 6, 12 and 24 months after CR. Samples were shipped to arrive at a central laboratory within 24 h (Lund) for isolation of mononuclear cells (MNC) and $CD34^+$ cells by density gradient technique (Lymphoprep; Axis Shield, Oslo, Norway) and magnetic bead cell sorting (MACS; Miltenyi Biotech, Bergisch-Gladbach, Germany) as previously described (Nilsson *et al*, 2002; Grövdal *et al*, 2007). Cells were stored as pellet at −80°C. Genomic DNA was isolated from MNC and $CD34^+$ cells using the QiAmp DNA mini kit (Qiagen, Hilden, Germany) according to manufacturer's guidelines. Bone marrow sampled in CR and during follow up frequently rendered an insufficient $CD34^+$ yield, and methylation analyses were therefore consequently performed on un-separated MNC, after first confirming a strong correlation between methylation results in $CD34^+$ and MNC on the pre-induction samples ($P < 0{\cdot}001$) (Grövdal *et al*, 2007). The amount of DNA obtained was measured by spectrophotometer (ND-100; Nano-Drop Technologies, Wilmington, DE, USA). DNA was further modified by sodium bisulfite as previously described (Zeschnigk *et al*, 1997; Grövdal *et al*, 2007).

Polymerase chain reaction (PCR) and denaturing gradient gel electrophoresis (DGGE)

PCR specific for bisulfite-reacted *CDKN2B*, *CDH1* and *HIC1* promoters was carried out as previously described (Aggerholm *et al*, 2006; Grövdal *et al*, 2007). Primer sequences were: [CCGCC]-GTTAGGAGTTTTTTTTTAGAAGTAATTT (*CDKN2B*: F), [GC3]-AAACTAAACTCAACTTCATTACCCTC (*CDKN2B*: R), [GC1]-GTTTATTTGGT-TGTAGTTA (*CDH1*: F), CTCCAAAAACCCATAACTAAC (*CDH1*: R), [GC1]-AT-AATT-AGAGTATTAAGGGTTTTTTGTG (*HIC1*: F), [CG-CCCGCCGC]-CACCCAAAAACT-TAAAATAAACACTACTA (*HIC1*: R). Nucleotides in brackets represent GC-clamps; [GC1] = CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCC CCCGCCCG, [GC3] = CCCGCCGCCCGCCGCTCGCCCGC CGCGCCCCGCGCCCGTCCCGCC-GCCCCCGCCCG. PCR results were examined by electrophoresis in a 2·5% agarose gel. Fifteen to 20 μl of the PCR product was loaded onto a 10% denaturant/6% polyacrylamide -70% denaturant/12% polyacrylamide gradient gel. A fully methylated control (SssI) and an unmethylated control (peripheral blood lymphocytes) were also loaded to each gel. Gels were run at 160 V for 270 min in 1× Tris acetate/EDTA buffer kept at a constant temperature specific for each gene examined as previously described (Aggerholm *et al*, 2006; Grövdal *et al*, 2007). After electrophoresis, the gels were stained in Tris acetate/EDTA buffer containing ethidium bromide (2 mg/ml) and photographed under UV transillumination. Samples were scored as methylated when bands were present on the gels below the band corresponding to the unmethylated control (Cremonesi *et al*, 1997; Aggerholm *et al*, 2006).

Pyrosequencing

In a fraction of samples, the DGGE results for *CDKN2B* ($N = 29$) and *CDH1* ($N = 19$) were compared in a blinded way to methylation analysis by pyrosequencing according to a previously described method, with a congruence of 80% and 84% respectively (Tost & Gut, 2007; Geli *et al*, 2008). In the present study, DGGE results are used when referring to methylation status data.

Statistics

Median haemoglobin levels during azacytidine maintenance were compared using Wilcoxon signed-rank test. Survival analyses were performed by the Kaplan-Meyer method and compared using the Log Rank test. A P-value $<0{\cdot}05$ was considered significant. The size of the material did not allow for an extended multivariate analyses to be performed. All statistical calculations were carried out using SPSS 15.0 software for windows (SPSS Inc, Chicago, IL, USA).

Results

Patients

Sixty patients (median age 68 years, range 54–83) were enrolled between February 2004 and June 2006, with the last follow up at 1 August, 2008, 24 months after the last CR was reported. Median follow up time was 20·0 months (4·5–52·3). Clinical CR data and methylation status before treatment has previously been reported (Grövdal *et al*, 2007). Of 24 patients (40%) who achieved CR, one underwent allogeneic stem cell transplantation and was taken off study, and 23 patients (median age 70 years, range 62–76) started maintenance therapy with azacytidine. Ten patients had MDS [refractory anaemia with excess blasts [RAEB]-1 (1) or RAEB-2 (9)], 10 patients had AML, and 3 CMML-2 with >10% blasts. All AML patients had AML with multilineage dysplasia following MDS according to WHO (Jaffe *et al*, 2001). The median blast count in this group was 36% (range 20–98). RAEB patients fulfilled the criteria for IPSS intermediate-2 or high risk, and the CMML patients had myelodysplastic features with marrow blasts >10%. Twelve patients had a favourable prognostic karyotype (normal or isolated-Y, del(5q) or del(20q)) according to the IPSS, six had a poor prognostic karyotype (≥3 aberrations or chromosome 7

abnormalities) and five had an intermediate karyotype (not fulfilling the criteria for good or poor) (Table I).

Feasibility and safety of azacytidine maintenance treatment

In case of grade 3 or 4 cytopenia or severe adverse event after azacytidine, the subsequent course was delayed for one week. However, according to protocol, a maintained interval between azacytidine courses was prioritized to dose and consequently, the protocol was amended when three of the first five patients treated with azacytidine 75 mg/m^2 developed grade 3 (n = 1) or 4 (n = 2) neutropenia. The new starting dose was 60 mg azacytidine per m^2 and further dose reductions were allowed to avoid severe cytopenias and hospitalization. The median dose of all administered azacytidine cycles was 56·3 mg/m^2 per day. The administered mean dose for each patient ranged between 30·0 and 63·3 mg/m^2. Median time between azacytidine courses was 29 days (20–53). The most frequent adverse event was grade 3 or 4 neutropenia which was reported at any time point in 43·5% and 30·5% patients respectively (Table II). However, only 22% (grade 3) and 8% (grade 4) of the total number of given courses were associated with neutropenia of this magnitude. Thrombocytopenia grade 3 occurred in 43·5% of the patients and after 9·5% of the courses. No grade 4 thrombocytopenia was reported. The majority of observed cytopenias preceded a relapse. Interestingly, haemoglobin levels rose during the first courses in 16/23 patients. Median haemoglobin level before azacytidine cycle 1 was 112 g/l (87–135) compared with 131 g/l (78–151) before cycle 4 (P = 0·02) (Fig 1). Local rash at the injection site was common and was reported for eight patients (35%). All adverse events are shown in Table II. All but one patient stopped azacytidine because of relapse. This patient had a thrombosis in the optic artery and lost vision in the affected eye.

CR duration

Median CR duration for the 23 azacytidine treated patients was 13·5 months (2–49+). Four patients (17%), without any obvious unifying characteristics, had a CR lasting for more than 24 months and two patients were still in CR at the last follow up. The study was not powered for subgroup analysis, however, no obvious differences in CR duration or survival were observed according to age or pre-induction diagnosis or cytogenetic subgroup (Fig 2). Pre-treatment platelet count below median was the only factor associated with time to relapse (P = 0·04). The actual maintenance dose given (above or below the median of 56·3 mg/m^2) did not affect time to relapse. Four out of five patients with a karyotype including trisomy 8 reached CR. Interestingly, all four had CR durations well above the median for the whole maintenance group (18–30·5 months).

A secondary objective of this study was to evaluate whether promoter methylation of selected genes could predict

Table I. Pre-induction characteristics of 23 patients receiving maintenance therapy with azacytidine.

Values at start of study	*N* = 23 (%)	Mean (SD)
Sex		
Male	12 (52)	
Female	11 (48)	
Age (years)		70 (62–76)*
Diagnosis WHO†		
MDS	10 (43·5)	
MDS-AML	10 (43·5)	
CMML	3 (13)	
Cytogenetic risk group IPSS‡		
Good	12 (52)	
Intermediate	5 (22)	
Poor	6 (26)	
Haemoglobin (g/l)		97 (10·1)
WBC (10^9/l)		6·5 (14·4)
Platelets (10^9/l)		121 (96·9)
S-LDH (µkat/l)		5·8 (5·5)
Bone marrow cellularity (%)		75 (21·4)
Bone marrow blasts (%)		26 (24·2)
Methylated *CDKN2B*	9/19 (47·4)	
Methylated *CDH1*	2/16 (12·5)	
Methylated *HIC1*	2/16 (12·5)	

MDS, myelodysplastic syndrome; AML, acute myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; WBC, white blood cell count; S-LDH, serum lactate dehydrogenase.
*Median and range.
†World Health Organization classification.
‡International Prognostic Scoring System (Good: Normal, del(5)q, del(20)q Poor: Complex (≥3 anormalities) or chromosome 7 anomalities Intermediate: Not fulfilling criteria for good or poor.

Table II. Adverse events.

	Patients *N* = 23 (%)	Courses *N* = 281 (%)
Rash at injection site	8 (35)	
*Myelosuppression**		
Thrombocytopenia		
Grade 0–1	9 (39)	223 (79·5)
Grade 2	4 (17·5)	31 (11)
Grade 3	10 (43·5)	27 (9·5)
Grade 4	0 (0)	0 (0)
Neutropenia		
Grade 0–1	3 (13)	124 (44·5)
Grade 2	3 (13)	72 (25·5)
Grade 3	10 (43·5)	61 (22)
Grade 4	7 (30·5)	23 (8)
Infectious disease	5 (22)	
Fatigue	3 (13)	
Muscle pain	3 (13)	
Nausea	2 (9)	
Thrombosis in optic artery	1 (4)	

*According to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 2.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf).



Fig 1. Peripheral blood counts during first six courses of azacytidine. Samples were taken immediately prior to the start of azacytidine. (A, C, E) Each line represents one patient during six cycles or until relapse. (B, D, E) Box plots. Boxes show median values and 25–75 percentile, whiskers represent maximum and minimum values, circles represent outliners (values between 1·5 and 3 box lengths from either end of the box) and asterisks represent extremes (values more than three box lengths from either end of the box). (A, B) Haemoglobin (g/l) (C, D) Platelets (10^9/l) (E, F) Neutrophils (10^9/l).

response to azacytidine. Eight of nine patients with promoter methylation of any of the analysed genes became unmethylated in CR. *CDKN2B* methylation status prior to induction chemotherapy did not correspond to CR duration ($P = 0{\cdot}82$). Only two of 15 patients with pre-treatment *CDH1* methylation reached CR and they both had very short CR durations (2·5 and 6 months, respectively). One patient developed *CDKN2B* methylation in the bone marrow sampled at 12 months after CR and relapsed shortly after, at 15·5 months. Figure 3 shows methylation status and relapse information for all patients.

Overall survival (OS)

Median OS for the 23 patients who received maintenance treatment was 20·0 months (4–52+) (Fig 4). Two year survival was 37·5% and 13·9%, in patients achieving CR and not achieving CR, respectively. Median OS for the whole cohort ($N = 60$) was 8·2 months (0·1–52·3+). *CDH1* was methylated in 15 of 41 evaluable patients pre-treatment. Median OS for the 15 patients with pre-treatment *CDH1* methylation was 4·0 months (0·1–15·7), compared to 9·3 months (0·5–43·5+) for patients without *CDH1* methylation ($P = 0{\cdot}003$). *CDKN2B*



Fig 2. CR duration. (A) All 23 patients on azacytidine maintenance (B) MDS-AML *versus* RAEB and CMML (C) Cytogenetics IPSS Good *versus* Intermediate and Poor (D) Platelet counts above median *versus* below median at study start (E) *CDKN2B* methylated *versus* unmethylated at study start (F) Patients given doses of azacytidine above *versus* below the mean dose.

methylation status did not affect survival (0·83). In addition a diagnosis of MDS-AML vs. RAEB or CMML, CD34+ expression and platelet counts below median were associated with shorter survival ($P = 0{\cdot}04$, 0·018 and 0·006 respectively) (Fig 4). There was no significant association between IPSS cytogenetic subgroup and survival.

Discussion

Prolonged therapy with azacytidine was recently shown to significantly improve survival and time to AML transformation in Intermediate-2 and high-risk MDS patients, according to a large randomized phase III trial, data that recently led to the approval of the drug by EMEA and that are likely to influence the European guidelines for treatment of this patient category (Fenaux *et al*, 2009). However, when the present study was designed in 2002, primary therapy for high-risk and transformed MDS in most parts of Northern Europe was moderate intensity induction chemotherapy or supportive care only. There is overwhelming evidence that disease recurs in the vast majority of patients achieving a CR unless allogeneic stem cell transplantation is performed. Most

 © 2010 Blackwell Publishing Ltd,



Fig 3. Methylation status. Methylation status for each of the 23 patients receiving azacytidine maintenance at the time points when bone marrow was sampled (study start, CR and 6, 12 and 24 months after CR) Patients with karyotype including trisomy 8 are marked with an asterisk.

patients relapse within the first year, and conventional consolidation chemotherapy does not seem to prolong CR duration (Wattel *et al*, 1997; Ganser *et al*, 2000; Hast *et al*, 2003; Kantarjian *et al*, 2006b; Hofmann *et al*, 2007). If there is a potential benefit from autologous stem cell transplantation, this is restricted to younger patients (De Witte *et al*, 1997; Wattel *et al*, 1999).

This trial is the first to evaluate safety and feasibility of maintenance treatment with azacytidine for patients with high-risk MDS and MDS-AML with CR after induction chemotherapy. The hypothesis was that azacytidine maintenance could prolong time to relapse and that the results might constitute a basis for a prospective randomized Phase III trial.

Azacytidine treatment was well tolerated at a starting dose of 60 mg/m^2 5/28 d, while higher doses, administered within 28 d from CR, induced high degree of grade 3 or 4 neutropenia. Also at the lower starting dose, the most common adverse event was grade 3 neutropenia and/or thrombocytopenia. Interestingly, azacytidine treatment rarely induced anaemia and in fact more than two thirds of the patients experienced an improvement in haemoglobin levels during the first months of treatment (Fig 1). As thrombocytopenia and neutropenia was common, this may not just reflect bone marrow recovery after induction chemotherapy but a positive direct effect of azacytidine on erythropoiesis. Other side effects were mild and manageable and only one patient stopped treatment due to side effects.

The CR duration of 13·5 months and OS of 20·0 months are not clearly different from previous studies on induction chemotherapy for patients with high-risk MDS or MDS-AML; however the majority of these studies included slightly younger patients (Hast *et al*, 2003; Ganser *et al*, 2000; Kantarjian *et al*, 2006a; Hofmann *et al*, 2007; Wattel *et al*, 1997). Studies on older patients with AML by the South Western Oncology Group (SWOG) and the Haemato-Oncology Foundation for Adults in the Netherlands (HOV-ON) group, which included both *de novo* cases and secondary AML, showed an OS of 9 and 10 months, respectively (Anderson *et al*, 2002). Clearly however, azacytidine did not seem to prevent relapses in the majority of the cases.

The question that remains to be investigated is whether relapse was delayed in a subset of patients. This present study was not powered to analyse subgroups. However, we concluded that there were no obvious differences in CR duration or OS with regard to age, diagnosis or cytogenetic subgroup, i.e. parameters that in other studies have appeared as prognostic markers for outcome (Wattel *et al*, 1997; Ganser *et al*, 2000; Kantarjian *et al*, 2006a). One interesting subgroup was patients with a karyotype including trisomy 8. Four out of five patients with trisomy 8 reached CR and all four had CR durations well above the median for the whole maintenance group. This is interesting, as a better response to azacytidince has also been previously reported among patients with trisomy 8 (Raj & Mufti, 2006). Our findings might support a positive effect of azacytidine maintenance in this group but could also just reflect a more robust response to induction chemotherapy. There are previous reports of differences in the immune response between MDS patients with trisomy 8 and other MDS (Kawabata *et al*, 2006; Meers *et al*, 2007) and also on the immunomodulatory effects of azacytidine (Laurenzana *et al*, 2009; Liu *et al*, 2009; Sánchez-Abarca *et al*, 2010). Whether immunomodulation, by demethylation or not, may explain the better overall outcome in this group remains to be studied. As previously reported by us, methylation of *CDH1* or of multiple genes was associated with a poor response to induction chemotherapy ($P = 0{\cdot}008$) (Grövdal *et al*, 2007). Hence, very few patients with any other gene than *CDKN2B* methylated actually reached CR and, accordingly, most of these patients never started azacytidine maintenance. In the whole study population, *CDH1* methylation was related to significantly shorter survival ($P = 0{\cdot}003$). The only two patients with *CDH1* methylation subjected to azacytidine maintenance relapsed early, after 2·5 and 6 months. This strengthens our previous observation that *CDH1* methylation is a marker for poor overall prognosis and poor response to induction chemotherapy. Interestingly, methylation status of *CDKN2B* was not correlated to CR duration or survival, which contradicts previous reports that *CDKN2B* methylation predicts a worse outcome (Christiansen *et al*, 2003; Aggerholm *et al*, 2006). Whether this reflects a selection bias, i.e. *CDKN2B* methylation will not add



Fig 4. Overall survival. (A) Overall survival for all 60 patients enrolled (B) MDS-AML *versus* RAEB and CMML (C) Bone marrow CD34+ above *versus* below the median level (D) Platelets at study start above *versus* below the median (E) *CDKN2B* methylated *versus* unmethylated at study start (F) *CDH1* methylated *versus* unmethylated at study start.

further to the risk profile in a cohort with a high proportion of other high-risk features and confirmed AML transformation, or if it may indicate that azacytidine maintenance actually counteracted the negative effect of *CDKN2B* methylation remains to be investigated. At this stage we can only conclude that methylation analysis of any of the three selected genes cannot be used to select patients for maintenance treatment with azacytidine.

Dose reduction of azacytidine was allowed to maintain dose interval and to avoid potential hospitalizing adverse events in this elderly patient group. Hence, insufficient azacytidine doses might have influenced the overall results. However, patients treated with doses above or below the median dose showed no differences with regard to any of the measured outcomes.

In the majority of patients with pre-treatment methylation of any of the three genes, achievement of CR was associated with a disappearance of methylation. Together with the finding of a development of *CDKN2B* methylation preceding relapse in one patient, this supports a previous report proposing promoter methylation as a marker for residual disease

(Agrawal *et al*, 2007). It may be of future interest to clarify whether this is due to demethylation of cells belonging to the clone, or if the methylated clone is reduced below detection level by cytostatic treatment.

This study is the first to evaluate azacytidine as maintenance treatment after successful induction chemotherapy in high-risk and transformed MDS. It showed that treatment was very well tolerated, with manageable neutropenia and thrombocytopenia, almost no inhibiting effect on erythropoiesis, and few other side effects. Although no overall positive effect on CR duration, the main efficacy criterion, was observed, certain subgroups of patients, such as those with trisomy 8, may be subject for further investigation. The strong negative effect of hypermethylation on outcome of chemotherapy is a finding that needs to be addressed in high-risk MDS, particularly in patients planned for allogeneic stem cell transplantation.

Disclosures

EHL, JMT and LK have been speaking at Celgene-supported educational events in the Nordic countries. EHL has been part of the advisory board for MDS 001 (azacytidine) and MDS 004 (lenalidomide).

Funding

This work was supported by the Nordic Cancer Union, the Swedish Cancer Society, the Cancer Society in Stockholm, and by an unrestricted grant from Pharmion 2004–2006 encompassing free drug and a limited support for GCP-costs.

References

Aggerholm, A., Holm, M.S., Guldberg, P., Olesen, L.H. & Hokland, P. (2006) Promoter hypermethylation of P15ink4b, HIC1, CDH1 and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early stage patients. *European Journal of Haematology*, **76,** 23–32.

Agrawal, S., Unterberg, M., Koschmieder, S., zur Stadt, U., Brunnberg, U., Verbeek, W., Büchner, T., Berdel, W.E., Serve, H. & Müller-Tidow, C. (2007) DNA methylation of tumor suppressor genes in clinical remission predicts relapse risk in acute myeloid leukemia. *Cancer Research*, **67,** 1370–1377.

Anderson, J.E., Kopecky, K.J., Willman, C.L., Head, D., O'Donnell, M.R., Luthardt, F.W., Norwood, T.H., Chen, I.M., Balcerzak, S.P., Johnson, D.B. & Appelbaum, F.R. (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. *Blood*, **12,** 3869–3876.

Berg, T., Guo, Y., Abdelkarim, M., Fliegauf, M. & Lübbert, M. (2007) Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and –negative myeloid leukemia cell lines. *Leukemia Research*, **31,** 497–506.

Christiansen, D.H., Andersen, M.K. & Pedersen-Bjergaard, J. (2003) Methylation of p15ink4b is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. *Leukemia*, **17,** 1813–1819.

Cremonesi, L., Firpo, S., Ferrari, M., Righetti, P.G. & Gelfi, C. (1997) Double-gradient DGGE for optimized detection of DNA point mutations. *BioTechniques*, **22,** 326–330.

Daskalakis, M., Nguyen, T.T., Nguyen, C., Guldberg, P., Köhler, G., Wijermans, P., Jones, P.A. & Lübbert, M. (2002) Demethylation of a hypermethylated p15/INK4b gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. *Blood*, **100,** 2957–2964.

De Witte, T., Van Biezen, A., Hermans, J., Labopin, M., Runde, V., Or, R., Meloni, G., Mauri, S.B., Carella, A., Apperley, J., Gratwohl, A. & Laporte, J.P. (1997) Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. *Blood*, **90,** 3853–3857.

Esteller, M. (2008) Epigenetics in cancer. *New England Journal of Medicine*, **358,** 1148–1159.

Fenaux, P., Mufti, G.J., Hellström-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R. (2009) Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label phase III study. *Lancet Oncology*, **3,** 223–232.

Ganser, A., Heil, G., Seipelt, G., Hofmann, W., Fischer, J.T., Langer, W., Brockhaus, W., Ittel, T.H., Brack, N., Fuhr, H.G., Knuth, P., Höffken, K., Bergmann, L. & Hoelzer, D. (2000) Intensive chemotherapy with idarubicine, ara-C, etoposide and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML). *Annals of Hematology*, **79,** 30–35.

Geli, J., Kiss, N., Karimi, M., Lee, J., Bäckdahl, M., Ekström, T.J. & Larsson, C. (2008) Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: Association to malignant behavior. *Clinical Cancer Research*, **9,** 2551–2559.

Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennet, J. (1997) International scoring system for evaluating the prognosis in myelodysplastic syndromes. *Blood*, **89,** 2079–2088.

Grønbaek, K., Treppendahl, M., Asmar, F. & Guldberg, P. (2008) Epigenetic changes in cancer as potential targets for profylaxis and maintenance therapy. *Basic & Clinical Pharmacology and Toxicology*, **103,** 389–396.

Grövdal, M., Khan, R., Aggerholm, A., Antunovic, P., Astermark, J., Bernell, P., Engström, L.M., Kjeldsen, L., Linder, O., Nilsson, L., Olsson, A., Wallvik, J., Tangen, J.M., Öberg, G., Jacobsen, L.E., Hokland, P., Porwit, A. & Hellström-Lindberg, E. (2007) Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. *Clinical Cancer Research*, **13,** 7107–7112.

Guo, Y., Engelhardt, M., Wider, D., Abdelkarim, M. & Lübbert, M. (2006) Effects of 5-aza-2′-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells. *Leukemia*, **20,** 115–121.

Hast, R., Hellström-Lindberg, E., Ohm, L., Björkholm, M., Celsing, F., Dahl, I.M., Dybedal, I., Gahrton, G., Lindberg, G., Lerner, R., Linder, O., Löfvenberg, E., Nilsson-Ehle, H., Paul, C., Samuelsson, J.,

Tangen, J.M., Tidefelt, U., Turesson, I., Wahlin, A., Winquist, I., Öberg, G. & Bernell, P. (2003) No benefit from adding GM-CSF to induction chemotherapy regimens in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. *Leukemia*, **17,** 1827–1833.

Hofmann, W.K., Heil, G., Zander, C., Wiebe, S., Ottmann, O.G., Bergmann, L., Hoeffken, K., Fischer, J.T., Knuth, A., Kolbe, K., Schmoll, H.J., Langer, W., Westerhausen, M., Koebel, C.B., Hoelzer, D. & Ganser, A. (2007) Intensive chemotherapy with idarubicine, cytarabine, etoposide and G-CSF priming in patients with advanced myelodysplastic syndrome ahd high-risk acute myeloid leukemia. *Annals of Hematology*, **83,** 498–503.

Jädersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A. & Hellström-Lindberg, E. (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. *Blood*, **106,** 803–811.

Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W., (ed.) (2001) *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoitetic and Lymphoid Tissues*. IARC Press, Lyon, France.

Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia-Manero, G., Wierda, W., Pierce, S., Shan, J. & Estey, E. (2006a) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. *Cancer*, **106,** 1090–1098.

Kantarjian, H., Beran, M., Cortes, J., O'Brien, S., Giles, F., Pierce, S., Shan, J., Plunkett, W., Keating, M. & Estey, E. (2006b) Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. *Cancer*, **106,** 1099–1109.

Kawabata, H., Sawaki, T., Kawanami, T., Shomovama, K., Karasawa, H., Fukushima, T., Masaki, Y., Ogawa, N., Hirose, Y., Ozaki, K., Shimanaka, K., Takase, S., Ueno, H. & Umehara, H. (2006) Myelodysplastic syndrome with inflammatory intestinal ulcers: significance of trisomy 8. *Internal Medicine*, **45,** 1309–1314.

Khan, R., Schmidt-Mende, J., Karimi, M., Gogvadze, V., Hassan, M., Ekström, T.J., Zhivotovsky, B. & Hellström-Lindberg, E. (2008) Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. *Experimental Hematology*, **36,** 149–157.

Laurenzana, A., Petruccelli, L.A., Pettersson, F., Figueroa, M.E., Melnick, A., Baldwin, A.S., Paoletti, F. & Miller, Jr, W.H.. (2009) Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. *Cancer Research*, **69,** 55–64.

Liu, Y., Kuick, R., Hanash, S. & Richardson, B. (2009) DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. *Clinical Immunology*, **130,** 213–224.

Lübbert, M., Wijermans, P., Kunzmann, R., Verhoef, G., Bosly, A., Ravoet, C., Andre, M. & Ferrant, A. (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA-methylation inhibitor 5-aza-2′-deoxycytidine. *British Journal of Haematology*, **114,** 349–357.

Meers, S., Kasran, A., Boon, L., Lemmens, J., Ravoet, C., Boogaerts, M., Verhoef, G., Verfaillie, C. & Delforge, M. (2007) Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40-CD40L interactions with T helper cells. *Leukemia*, **21,** 2411–2419.

Nilsson, L., Åstrand-Grundström, I., Andersson, K., Arvidsson, I., Hokland, P., Bryder, D., Kjeldsen, L., Johansson, B., Hellström-Lindberg, E., Hast, R. & Jacobsen, L.E. (2002) Involvement and functional impairment of the CD34+ CD38- hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. *Blood*, **100,** 259–267.

O'Dwyer, K. & Maslak, P. (2008) Azacitidine and the beginnings of therapeutic epigenetic modulation. *Expert Opinion on Pharmacotherapy*, **9,** 1981–1986.

Raj, K. & Mufti, G.J. (2006) Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes. *Therapeutics and Clinical Risk Managagment*, **2,** 377–388.

Sánchez-Abarca, L.I., Gutierrez-Cosio, S., Santamaría, C., Caballero-Velazquez, T., Blanco, B., Herrero-Sánchez, C., García, J.L., Carrancio, S., Hernández-Campo, P., González, F.J., Flores, T., Ciudad, L., Ballestar, E., Del Cañizo, C., San Miguel, J.F. & Pérez-Simon, J.A. (2010) Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. *Blood*, **115,** 107–121.

Schmeltz, K., Sattler, N., Wagner, M., Lübbert, M., Dörken, B. & Tamm, I. (2005) Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) byt not epithelial cells by DNA-methylation-dependent and –independent mechanisms. *Leukemia*, **19,** 103–111.

Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., De Castro, C.M., Ellerton, J., Larson, R.A., Schiffer, C.A. & Holland, J.F. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. *Journal of Clinical Oncology*, **20,** 2429–2440.

Singal, R. & Ginder, G.D. (1999) DNA methylation. *Blood*, **93,** 4059–4070.

Tien, H.F., Tang, J.L., Tsay, W., Liu, M.C., Lee, F.Y., Wang, C.H., Chen, Y.C. & Shen, M.C. (2001) Methylation of the p15ink4b gene in myelodysplastic syndrome: it can be detected early at diagnosis or during progression and is highly associated with leukaemic transformation. *British Journal of Haematology*, **112,** 148–154.

Tost, J. & Gut, I.G. (2007) DNA methylation analysis by pyrosequencing. *Nature Protocols*, **9,** 2265–2275.

Wattel, E., De Botton, S., Laï, J.L., Preudhomme C., Lepelley.P., Bauters, F. & Fenaux, P. (1997) Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. *British Journal of Haematology*, **98,** 983–991.

Wattel, E., Solary, E., Leleu, X., Dreyfus, F., Brion, A., Jouet, J.P., Hoang-Ngoc, L., Maloisel, F., Guerci, A., Rochant, H., Gratecos, N., Casassus, P., Janvier, M., Brice, P., Lepelley, P. & Fenaux, P. (1999) A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. *Leukemia*, **13,** 524–529.

Zeschnigk, M., Lich, C., Buiting, K., Doerfler, W. & Horsthemke, B. (1997) A single-tube PCR-test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. *European Journal of Human Genetics*, **5,** 94–98.